TEST:

DefineMBC™

DefineMBC combines several multi-analyte assay methods to perform comprehensive cancer profiling and has demonstrated impressive sensitivity, specificity, accuracy, and precision. Detects circulating tumor cells (CTCs), and quantification of ER and HER2 protein expression on those cells, through immunofluorescent staining combined with image analysis by an algorithm developed through advanced machine learning. Whole-genome sequencing of individual CTCs (called single-cell sequencing) to detect presence of amplified cancer-related genes through analysis of copy number variation provide Isolation and characterization of the copy number variation (CNV). Analysis of cell-free DNA (cfDNA) by next-generation sequencing (NGS) of 56 genes, the detection of genomic alterations [single nucleotide variants (SNVs), fusions, CNVs, microsatellite instability (MSI), and tumor mutational burden (TMB)]. Expanded coverage of up to 500 genes is available for research and biopharma trials.